Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report.
Medicine (Baltimore)
; 100(12): e25173, 2021 Mar 26.
Article
in English
| MEDLINE | ID: covidwho-1150008
ABSTRACT
RATIONALE Bacterial and fungal infections in Coronavirus Disease-19 (COVID-19) patients have been inadequately investigated and reported thus far. The safety profile of tocilizumab (TCZ) administration in candidemia patient still debatable. PATIENT CONCERNS A 54 year-old woman presenting with weakness on the left side of her body was diagnosed with COVID-19. After 7âdays of admission, her condition worsened and developed respiratory distress and was having respiratory distress despite standard treatment. DIAGNOSES Acute respiratory distress syndrome (ARDS) in COVID 19 was diagnoses based on real time-PCR swab, deterioration of PaO2/FiO2 and increased of acute phase reactants. INTERVENTIONS:
Anti Interleukin-6 (IL-6) was considered to tackle her inflammatory condition. Prior to TCZ administration, blood culture was performed and the result came with Candida tropicalis in the absence of bacterial growth.OUTCOMES:
No major complications associated with intravenous antifungal or TCZ occurred. After 40âdays of hospitalization, the patient's clinical condition improved and was finally discharged. LESSONS This case underscores the safety profile of giving TCZ in candidemia as a secondary infection in severe COVID-19 patient.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin-6
/
Candidemia
/
Antibodies, Monoclonal, Humanized
/
COVID-19
/
COVID-19 Drug Treatment
/
Antifungal Agents
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Medicine (Baltimore)
Year:
2021
Document Type:
Article
Affiliation country:
MD.0000000000025173
Similar
MEDLINE
...
LILACS
LIS